

VACCINE PREVENTABLE DISEASES IN THE XXI CENTURY

Maria Catalina Pérez

This editorial may be cited as: Pérez MC. Vaccine Preventable Diseases in the XXI Century. J Postgrad Med Inst 2012; 26(4):349-51.

All over the world, both in developing and developed countries there are public health authorities and other organizations that are making the best effort to reduce morbidity and mortality of children due to vaccine preventable diseases. At this moment this is mandatory in many countries because by reducing morbidity and mortality, vaccination can contribute substantially to achieve the Millennium Development Goal of reducing the mortality rate among children under five years by two thirds between 1990 and 2015.

The vaccination is one of the most cost-effective strategies to control infectious diseases, even at this moment when new and more expensive vaccines are needed^{1,2}.

Pneumonia³, neonatal severe infections (most of them pneumonia), measles⁴, diarrheal disease, neonatal tetanus and meningitis represent the most frequent vaccine preventable diseases.

There are available vaccines that have demonstrated that it is possible to reduce significantly the incidence of infection by bacteria and viruses that cause pneumonia in children, e.g. vaccines against *S. pneumoniae* (pneumococcal conjugated vaccine 7,10 or 13 valent)⁵, conjugated vaccine against *Haemophilus influenzae* type b, acellular or cellular *Bordetella pertussis* vaccines, pneumonia caused by influenza virus and measles virus or varicella virus.

With vaccines, it is possible to reduce significantly the incidence of severe diarrhoea caused by rotavirus, one of the most frequent cause of diarrhea⁶.

Vaccines against measles⁴ and tetanus have high effectiveness if the children receive the doses at the age indicated by vaccine schedules in different countries. It is not any more acceptable that these diseases are in the list of the ones that cause death in children. Data from different studies suggest the need for systematic review of vaccine-preventable incidents to examine the effect of exemptions, increased surveillance of the number of exemptions and cases among them, and research to determine the reasons why individuals claim exemptions⁷. Studies provide evidence that MMR or a single measles vaccine does not have adverse effects, such as for example autism⁸.

There are conjugated vaccines with high efficacy and effectiveness to reduce the incidence of meningitis caused by *S. pneumoniae*, *H. influenzae* type b and *N. meningitidis* A, C, Y and W135⁹. The available vaccines to control infections by *N. meningitidis* type B are not appropriate to control outbreaks or endemic disease in different regions of the world, but there are big efforts to demonstrate the safety, immunogenicity, and tolerability of the new recombinant meningococcal serogroup B vaccines (the 4CmenB vaccine and the recombinant lipoprotein 2086 vaccine) or to improve the old vaccines.

Department of Paediatrics, University of Republic of Uruguay, Montevideo - Uruguay

Address for Correspondence:

Dr. Maria Catalina Pérez,
Professor of Clinical Paediatrics,
Faculty of Medicine,
University of Republic of Uruguay, Montevideo -
Uruguay
E-mail: mcpirez@yahoo.com

All the vaccines, including the old and the new ones, can offer a chance for children to live healthy and not die because of vaccine preventable diseases. All the potential benefits that the vaccination can offer to the public health does not only depend on the maintenance of the vaccines or the introduction of new ones in the vaccination schedule, but also on achieving high coverage for all primary doses and boosters.

If high vaccination coverage¹⁰ (up to 90 %) is not

achieved, the effectiveness of vaccination will not be optimal and the herd immunity that some vaccines can provide to the whole population could not be considered as an additional benefit of the national immunization programs (NIP)¹¹.

One of the reasons that tetanus, measles and polio are still public health problems is that communities have not enough information about the importance of receiving all vaccine doses at the age recommended in the NIP. The vaccination can control infectious diseases like pneumonia, diarrhoea and bacterial meningitis¹², but in order to be able to achieve this goal, the objective must be to strengthen partnership between researchers, people involved in health care and whole community in providing benefits of vaccination to entire communities and sharing information on importance of this strategy in reduction of mortality in children¹³.

REFERENCES

1. Chumakov K, Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. *Clin Infect Dis* 2008;47:1587-92
2. Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. *MMWR Recomm Rep* 2010; 59:1-18.
3. De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, Petit S, et al. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. *Vaccine* 2012;30:4067-72.
4. Atkinson W, Wolfe C, Humiston S, Nelson R. Measles. In: Atkinson W, Wolfe C, editors. *Epidemiology and prevention of vaccine-preventable diseases*. 7th ed. USA: Centers for Disease Control and Prevention (CDC); 2002.
5. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (pcv13) coverage among children aged ≤59 months -- selected U.S. regions, 2010-2011. *MMWR Morb Mortal Wkly Rep* 2011;60:1477-81.
6. Cortese MM, Parashar UD; Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2009;58:1-25.
7. Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT. Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risks of measles. *JAMA*1999;282:47-53.
8. Mrozek-Budzyn D, Kieltyka A, Majewska R. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. *Pediatr Infect Dis J* 2010;29:397-400.
9. Centers for Disease Control and Prevention (CDC). Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. *MMWR Morb Mortal Wkly Rep* 2011;60:1391-2.
10. Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among children aged 19-35 months--United States, 2010. *MMWR Morb Mortal Wkly Rep* 2011;60:1157-63.
11. Centers for Disease Control and Prevention (CDC). Progress toward Poliomyelitis Eradication--Afghanistan and Pakistan, January 2010--September 2011. *MMWR Morb Mortal Wkly Rep* 2011;60:1482-6.
12. Clarke C, Mallonee S. State-based surveillance to determine trends in meningococcal disease. *Public Health Rep* 2009;124:280-7.

13. Centers for Disease Control and Prevention (CDC). Vaccination Coverage among Children in Kindergarten --United States, 2009-10 School Year. MMWR Morb Mortal Wkly Rep 2011;60:700-4.